Literature DB >> 26039615

Management of potential bioterrorism-related conditions.

Amesh A Adalja, Eric Toner, Thomas V Inglesby.   

Abstract

Mesh：

Year:  2015        PMID： 26039615     DOI： 10.1056/NEJMc1504248

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E.

Authors:  S M Raja; J T Guptill; V C Juel; E B Walter; M Cohen-Wolkowiez; H Hill; E Sendra; B Hauser; P Jackson; M Tomic; Y Espinoza; G K Swamy
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

2.  Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.

Authors:  Brent J Yamamoto; Annette M Shadiack; Sarah Carpenter; Daniel Sanford; Lisa N Henning; Nestor Gonzales; Edward O'Connor; Leslie S Casey; Natalya V Serbina
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.